MetaVia Inc宣布其针对代谢疾病的候选药物Da-1726在一期B期临床试验中取得具有统计学意义的积极数据。该试验结果显示,Da-1726不仅能有效调控血糖水平,还展现出对肝脏的直接作用机制。此外,受试者在接受治疗后出现显著的体重下降,同时药物整体安全性表现优异,未出现严重不良反应。
MetaVia Inc宣布其针对代谢疾病的候选药物Da-1726在一期B期临床试验中取得具有统计学意义的积极数据。该试验结果显示,Da-1726不仅能有效调控血糖水平,还展现出对肝脏的直接作用机制。此外,受试者在接受治疗后出现显著的体重下降,同时药物整体安全性表现优异,未出现严重不良反应。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.